|Sun Pharma Advanced Research Company Limited|
Sun Pharma Advanced Research Centre
India - Map
Sun Pharma Advanced Research Company Limited operates as a pharma research and drug discovery company. It develops SUN 1334H, which has completed phase II clinical studies, used in the treatment of allergic disorders, such as seasonal and perennial allergic rhinitis, urticaria, hay fever, conjunctivitis, and pruritis; and Sun K706, a novel tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. The company also offers SUN-597, an anti-inflammatory glucocorticoid that has completed preclinical development used for the treatment of allergic rhinitis, inflammation, asthma, and other applications; and Sun 44, a prodrug of gabapentin for the treatment of epilepsy, as well as for the treatment of neuropathic pain, restless leg syndrome, and mood disorders. In addition, it provides SUN-09, a prodrug of baclofen that has completed phase I studies for the treatment of spasticity; and SUN-L731, an oral LTD4 antagonist for asthma and allergic rhinitis. Further, the company offers gastro retentive innovative device, a once-a-day delivery system for drugs; wrap matrix oral delivery system; paclitaxel injection concentrate for nanodispersion for the treatment of breast cancer; docetaxel injection concentrate for nanodispersion for non-small cell lung cancer; and octreotide depot injections for treatment of prostate cancer and acromegaly. Additionally, the company provides salmeterol and fluticasone dry powder inhaler, a pre-metered inhalation activated device for administration of inhaled steroids and bronchodilator drugs for the treatment of asthma and COPD; swollen micelle microemulsion technology, a platform technology for solubilising ophthalmic drugs with limited or no water solubility; and gel free reservoir technology used for the treatment of chronic eye ailments, such as glaucoma. Sun Pharma Advanced Research Company Limited is based in Vadodara, India.
|Mr. Dilip Shantilal Shanghvi ,
Chairman and Managing Director
|Dr. Rajamannar Thennati ,
Exec. VP of R&D, Wholetime Director, Chairman of Fund Mobilising & Monitoring Committee and Member of Shareholders'/Investors' Grievance Committee
|Ms. Meetal S. Sampat ,
Compliance Officer and Company Sec.
|Dr. Subhas Bhowmick ,
VP of R&D (Formulation)
|Dr. K. Shivramchandra ,
VP of R&D (Analytical Devel.)
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in INR.|